Survey of Susoctocog Alfa Intravenous Injection in People with Acquired Hemophilia A in Japan

What this Trial Is About

This research aims to evaluate the use of Susoctocog Alfa Genetical Recombination intravenous injection in participants with bleeding events caused by acquired Hemophilia A AHA in Japan. The study focuses on monitoring side effects related to this drug and assessing its impact on bleeding episodes in this condition. The sponsor will not influence treatment decisions but will guide clinics on how to document patient outcomes. Participants will receive Susoctocog Alfa Genetical Recombination intravenously according to their clinics standard practice for AHA. The study observes the treatment as it is normally given without altering care. There is no placebo or comparison group. The drug administration and monitoring are part of routine clinical care during the study period. Throughout the study, participants will be followed for side effects from the first dose until up to 90 days after the last dose or until they stop treatment. Researchers will collect data on adverse events and treatment effectiveness as judged by investigators. The total study duration per participant varies depending on treatment and discontinuation timing, with safety checks continuing after treatment ends.

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A